Medical Heart Articles & Analysis
52 news found
The HFSA Optimal Medical Therapy in Heart Failure (OMT-HF) program can help your patients achieve their best outcomes. An estimated 6.5 million Americans have heart failure (HF). This year alone another 960,000 will likely be diagnosed with this condition. ...
$5.5M financing led by Taiho Ventures LLC, with participation of existing investors, including the Series Seed lead, Kizoo Technology Capital GmbH Fresh capital to be employed to get cellvie Series A ready by accelerating the development of the company's technology platform, strengthening the team, and advancing the mitochondria's GMP manufacturing cellvie Inc., a leader in Therapeutic ...
DSR (Direct Sodium Removal) heart failure drug development: Completed enrollment in SAHARA I[i] with first-generation DSR product (“DSR 1.0”) – extending study with second-generation DSR product (“DSR 2.0”) to support US IND[ii] filing by year end Proof-of-concept delivered in diuretic-resistant heart failure patients with ...
“The chronic and progressive nature of heart failure leaves many patients to face an increasingly challenging future as existing treatments, including medications and pacemaker devices, are not able to keep the disease at bay,” said Ulrich P. ...
Richardson has over 30 years of experience in the medical device industry, and an extensive record of successfully taking medtech companies from startup to commercialization to acquisition. Most recently, he was President and CEO of Keystone Heart, a structural heart medical device company, and creator of the first Cerebral ...
BySafeHeal
Blinded, multi-center study with analysis by an independent core laboratory Results to be presented for the first time at Heart Rhythm 2022 Vektor Medical today announced positive results from its “Vektor vMap™ Clinical Validation Study” evaluating the accuracy of cardiac mapping with vMap™. ...
XC001: Locally administered, single-dose gene therapy candidate to address the unmet need in refractory angina XyloCor’s lead investigational drug, XC001 (encoberminogene rezmadenovec), is under development as a novel approach to treating patients with refractory angina who have exhausted other medical and surgical options. This investigational gene therapy is designed to ...
“Advancing medication safety and clinical outcomes is critical for a hospital, and we’re honored to support Deborah Heart’s efforts to protect patient ...
Innovative technology The device has practical medical applications, particularly in detecting heart irregularities. ...
BySky Labs
“Nasdaq’s long tradition of listing category-defining medical technology companies aligns well with Daxor’s innovative blood volume technology portfolio,” commented Michael Feldschuh, CEO and President of Daxor. ...
JenaValve is backed by Bain Capital Life Sciences and Cormorant Asset Management as well as European and Asian investors, including Andera Partners, Gimv (Euronext: GIMB), Legend Capital, NeoMed Management, RMM, Valiance Life Sciences, VI Partners, and Peijia Medical Limited (HKEX: 9996). About Peijia Medical Peijia Medical was founded in 2012, ...
The BVA technology enhances hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. ...
Blood volume analysis is an important measure of health, surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. ...
Blood volume analysis is an important measure of health, surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. ...
We are actively developing hardware and software solutions embodying these patented concepts—with the support of the National Institutes of Health—to help all clinicians achieve the kind of improved outcomes demonstrated by experts using blood-volume-guided treatment for conditions such as heart failure and trauma.” “This patent award is a significant ...
Seth Goldbarg receives compensation in his role on the scientific advisory board for Volta Medical and the steering committee for the Tailored AF Trial. Dr. Goldbarg also owns shares in Volta Medical. ...
Orixha have developed a breakthrough proprietary Total Liquid Ventilation technology to improve clinical outcomes for patients in Critical Care and Intensive Care. The Vent2Cool medical device shields the brain and heart of resuscitated cardiac arrest patients from the reperfusion-induced cytokine storm. ...
These data from two separate studies were presented at the American Heart Association (AHA) Scientific Sessions virtual meeting from November 13-15, 2021. ...
About Daxor Corporation Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations). We developed and market the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by ...
Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure, today announced the first implantation of a patient in China with its innovative Optimizer system delivering CCM therapy. ...